These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. Safdar Z Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170 [TBL] [Abstract][Full Text] [Related]
4. An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs. Lundstrom K Methods Mol Biol; 2009; 552():51-66. PubMed ID: 19513641 [TBL] [Abstract][Full Text] [Related]
5. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Waxman AB Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185 [TBL] [Abstract][Full Text] [Related]
7. Acyl substitution at the ortho position of anilides enhances oral bioavailability of thiophene sulfonamides: TBC3214, an ETA selective endothelin antagonist. Wu C; Decker ER; Blok N; Li J; Bourgoyne AR; Bui H; Keller KM; Knowles V; Li W; Stavros FD; Holland GW; Brock TA; Dixon RA J Med Chem; 2001 Apr; 44(8):1211-6. PubMed ID: 11312921 [TBL] [Abstract][Full Text] [Related]
8. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. Wu C; Chan MF; Stavros F; Raju B; Okun I; Mong S; Keller KM; Brock T; Kogan TP; Dixon RA J Med Chem; 1997 May; 40(11):1690-7. PubMed ID: 9171878 [TBL] [Abstract][Full Text] [Related]
9. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. Wu C; Decker ER; Blok N; Bui H; You TJ; Wang J; Bourgoyne AR; Knowles V; Berens KL; Holland GW; Brock TA; Dixon RA J Med Chem; 2004 Apr; 47(8):1969-86. PubMed ID: 15055997 [TBL] [Abstract][Full Text] [Related]
10. Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists. Murugesan N; Gu Z; Stein PD; Spergel S; Mathur A; Leith L; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Morrison RA; Webb ML; Moreland S; Barrish JC J Med Chem; 2000 Aug; 43(16):3111-7. PubMed ID: 10956219 [TBL] [Abstract][Full Text] [Related]
11. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366 [TBL] [Abstract][Full Text] [Related]
12. Endothelin antagonists: substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors. Wu C; Decker ER; Blok N; Bui H; Chen Q; Raju B; Bourgoyne AR; Knowles V; Biediger RJ; Market RV; Lin S; Dupré B; Kogan TP; Holland GW; Brock TA; Dixon RA J Med Chem; 1999 Nov; 42(22):4485-99. PubMed ID: 10579813 [TBL] [Abstract][Full Text] [Related]